FUNDAMENTALS · Fundamentals · US Healthcare

BillionToOne (BLLN) Fundamentals 2026 — P/E 250.6x, Revenue Analysis | SniperIQ

BillionToOne (BLLN) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $5.9B, trading at

28.98 on the NASDAQ. This SniperIQ fundamentals page covers BillionToOne's valuation (P/E 250.6x, P/B 11.7x), profitability (net margin 7.1%), revenue (
05M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$5.9B
P/E (TTM)250.6x
Net Margin7.1%
Revenue (FY25)
05M

Full research coverage

Frequently Asked Questions

What is BillionToOne's market cap?

BillionToOne (BLLN) has a market capitalization of approximately $5.9B, trading at

28.98 on the NASDAQ. Market cap moves with the live share price.

What is BillionToOne's P/E ratio?

BillionToOne's trailing twelve-month P/E ratio is 250.6x, with a price-to-book (P/B) of 11.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is BillionToOne?

BillionToOne runs a net profit margin of 7.1%, a gross margin of 70.4%, and an operating margin of 10.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does BillionToOne generate?

BillionToOne reported revenue of

05M for fiscal year 2025, with net income of $7M and earnings per share (EPS) of 0.0637. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does BillionToOne pay a dividend?

BillionToOne does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is BillionToOne financially healthy?

BillionToOne carries a debt-to-equity ratio of 0.29x and a current ratio of 10.92x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is BillionToOne a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BillionToOne (BLLN) the key facts are: market cap $5.9B, P/E 250.6x, revenue

05M, 52-week range 61.96-138.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track BillionToOne's full fundamentals live

Get BillionToOne's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.